Combining anti-VEGF approaches with oxaliplatin in advanced colorectal cancer

Keyphrases

• Vascular Endothelial Growth Factor 100%
• Colorectal Cancer 100%
• Anti-vascular Endothelial Growth Factor (anti-VEGF) 100%
• Oxaliplatin 100%
• Advanced Colorectal Cancer 100%
• Factor Approach 100%
• 5-fluorouracil (5-FU) 66%
• Angiogenesis 66%
• Metastatic Colorectal Cancer (mCRC) 66%
• Targeted Agents 33%
• Monoclonal Antibody 33%
• Tyrosine Kinase Inhibitor 33%
• Malignancy 33%
• Overexpression 33%
• Poor Prognosis 33%
• Chemotherapy 33%
• Bevacizumab 33%
• Antiangiogenic Agents 33%
• Tumor Growth 33%
• Vascular Endothelial Growth Factor Receptor (VEGFR) 33%
• Blood Vessels 33%
• Antiangiogenic Therapy 33%
• Tumor Metastasis 33%
• Survival Benefit 33%
• Aggressive Disease 33%
• Tumor Vascularization 33%
• Antiangiogenic 33%
• Angiogenesis Inhibitors 33%
• Recombinant Antibody 33%
• First-line Therapy 33%
• FOLFOX 33%
• Leucovorin 33%
• PTK787 33%
• Vatalanib 33%
• Vital Process 33%

Medicine and Dentistry

• Vasculotropin 100%
• Colorectal Carcinoma 100%
• Oxaliplatin 100%
• Vatalanib 75%
• Monoclonal Antibody 50%
• Fluorouracil 50%
• Angiogenesis Inhibitor 50%
• Angiogenesis 50%
• Metastatic Colorectal Cancer 50%
• Neoplasm 25%
• Tumor Progression 25%
• Cancer 25%
• Bevacizumab 25%
• Metastatic Carcinoma 25%
• Vascularity 25%
• Vascular Bundle 25%
• Antiangiogenic 25%
• Tyrosine-Kinase Inhibitor 25%
• Antiangiogenic Therapy 25%
• Vasculotropin Receptor 25%
• FOLFOX 25%
• Folinic Acid 25%
• Diseases 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Vasculotropin 100%
• Oxaliplatin 100%
• Colorectal Carcinoma 100%
• Vatalanib 75%
• Monoclonal Antibody 50%
• Fluorouracil 50%
• Angiogenesis Inhibitor 50%
• Metastatic Colorectal Cancer 50%
• Neoplasm 25%
• Protein Tyrosine Kinase Inhibitor 25%
• Chemotherapy 25%
• Bevacizumab 25%
• Tumor Growth 25%
• Antiangiogenic Therapy 25%
• Antiangiogenic 25%
• Vasculotropin Receptor 25%
• Folinic Acid 25%
• Diseases 25%